title: The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.
abstract: The interval between courses of chemotherapy have classically been kept to a minimum in order to maximize dose intensity. Certain clinical observations suggest that longer intervals, particularly in the high-dose setting, may be more effective. This is based in part on the evidence that resistance is reversible over time and that the interval should be sufficient to allow for such a reversal. Clinical evidence for such reversibility include the following. In metastatic breast cancer, double or double high-dose stem cell rescue (HD-SCR) studies involving a minimal interval, have not, at least as yet, been shown to be superior to single HD-SCR. In Hodgkin's disease, response after relapse correlates directly with duration of time to relapse. In a comparative study of metastatic breast cancer, early HD-SCR preceded by daunorubicin induction was inferior to delayed HD-SCR. The latter was not preceded by induction chemotherapy. In a comparative study of childhood ALL, patients randomized to delayed (4 month interval) intensification had a significantly superior survival as compared to patients randomized to immediate (1 month interval) intensification. Taken together, these clinical observations indicate that resistance is reversible and that optimization of the interval must take this into account. Cytokinetic modeling of those clinical studies also found that delayed HD-SCR could result in a superior effect. Cytokinetic models of minimal residual tumor which were also examined included the Skipper exponential model, the Norton-Simon model which emphasizes the Gompertzian effect, the clonal evolution model, and the Retsky-Demisheli model which derives from a bimodal relapse pattern above. Biological and clinical data have resulted in a clinical protocol in the CALGB wherein patients with metastatic breast cancer are randomly allocated to (1) a single HD-SCR arm; (2) a double HD-SCR with a 5-week interval; and (3) a double HD-SCR arm with a 16 week interval.
authors.affiliation: Dana Farber Cancer Institute, Department of Adult Oncology, Boston, MA 02115, USA.
authors.forename: E
authors.initials: E
authors.lastname: Frei
authors.forename: P
authors.initials: P
authors.lastname: Richardson
authors.forename: D
authors.initials: D
authors.lastname: Avigan
authors.forename: C
authors.initials: C
authors.lastname: Bunnell
authors.forename: C
authors.initials: C
authors.lastname: Wheeler
authors.forename: A
authors.initials: A
authors.lastname: Elias
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000628:therapy; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy*; D012008:Recurrence; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents